Welcome to Markets Desk, your midday read on what's moving the needle.
UCB's CIMZIA just picked up a significant regulatory tailwind. The FDA granted Breakthrough Therapy Designation to the biologic drug for preventing placenta-mediated pregnancy complications in women with antiphospholipid syndrome. That designation accelerates development and review timelines, and signals the agency sees meaningful clinical promise here.
Shifting to private credit, Jefferies Credit Partners has launched a four billion dollar European direct lending strategy, anchored by the first close of its inaugural European fund. This is a notable expansion of the direct lending market into Europe at a time when traditional bank lending remains constrained across the continent, and institutional appetite for private credit continues to grow.
And in fintech, SoFi remains a name dividing the market. Despite broadly negative sentiment weighing on the stock, some analysts are making the case that the selloff is overdone, pointing to the company's expanding product suite and improving deposit base as reasons to stay constructive on the name heading into the next earnings cycle.
That's the tape. Markets Desk, signing off the floor.
